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The previous articles in this supplement have recounted, in detail, a number of the findings of the Global Orthopaedic Registry (GLORY) and placed them within the context of current knowl-
edge regarding anticoagulation in patients undergoing 
total hip arthroplasty (THA) and total knee arthroplasty 
(TKA). Furthermore, because of  the multinational nature 
of GLORY, we have been able to provide a preliminary 
view of some of the geographical differences in orthopedic 
practices that occur.
The first article provided an introduction to GLORY’s 
methodology, strengths, and limitations.1 The 3 main 
papers in this supplement  then showed GLORY results 
on orthopedic practice,2 venous thromboembolism (VTE) 
prophylaxis practice after THA and TKA,3 and complica-
tions and outcomes.4
The final GLORY data set encompassed 15,020 pro-
spectively enrolled patients (6,695 THA and 8,325 TKA 
patients), with a 70% follow-up rate at 3 and/or 12 months. 
These patients were enrolled between 2001 and 2004, 
providing a contemporary data set assessing current clini-
cal practice in THA and TKA. This data set will therefore 
provide a valuable reference source for current practice but 
should, of course, be superseded in the future.
The aim of the GLORY registry is to provide epide-
miological data from real-life practice, supplementing 
information provided by clinical trials. These data can 
provide insight into possible disparities between evidence-
based guidelines and real-life practice.1 Furthermore, if 
sufficient data are collected, a risk factors assessment can 
be performed to identify risk factors for VTE, bleeding, or 
other complications.
It is widely accepted that a major role of registries 
is to provide data that are hypothesis forming and thus 
could require stricter evaluation in controlled clinical tri-
als. A further advantage of this registry lies in its ability 
to help shape the future design of registries. To this end, 
we present here some of the more striking observations 
from GLORY, both in terms of conducting a registry of 
contemporary orthopedic procedures, and in suggesting 
some future work that has come out of the observations 
from GLORY.
Shaping Future  
Study deSign
In an editorial relating to acute coronary syndrome registries, 
12 key suggestions were defined to assess the quality of reg-
istries that, if followed, would improve the ability to compare 
between registries5 (Table). Although these suggestions were 
made in relation to acute coronary syndrome registries, they 
are sufficiently broad to apply to other scientific areas. It is 
therefore interesting to note that the GLORY registry design 
met 11 of the 12 criteria defined in this editorial.
In order to produce a large volume of robust data, it is 
the opinion of the GLORY investigators that a designated 
central coordinating center is required. It has become clear 
that in order to run a large international registry and gather 
robust data, a central coordinating center and adequate 
funding are vital. Underestimating the required resources 
will likely lead to poor follow-up and, as a result, reduce 
the value of collected data. Furthermore, careful prospec-
tive design of the study (i.e., case report form [CRF] 
design) is important to ensure that valuable data are gath-
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“The aim of the GLORY regis-
try is to provide epidemiologi-
cal data from real-life practice, 
supplementing information 
provided by clinical trials.”
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ered without putting too much of a burden on study coordi-
nators. If the time required to complete and submit the CRF 
is too lengthy, there will likely be an impact on enrollment 
and follow-up figures. It is therefore our recommendation 
that the initial step in setting up a new registry should be 
the formation of a steering committee whose members 
meet to discuss study design.
Current praCtiCe patternS
The data that have been outlined in the preceding pages of 
this supplement can be used in multiple ways.  Firstly, they 
should be viewed as giving a contemporary view of current 
THA and TKA practices, from both the surgical and throm-
boprophylactic viewpoints, in both the United States and 
other countries. Secondly, they also provide valid epide-
miological data on the rates of all complications in patients 
who underwent THA and TKA and received some form 
of prophylaxis. Thirdly, the data derived from this registry 
can be used to provide individual participating hospitals 
with specific feedback on practices as well as healthcare 
management with guidance on where improvement may 
be likely to be achievable. The provision of data back to 
participating physicians is valuable for self-assessment and 
a great motivation for their participation.
Key Findings
The results of the GLORY registry describe a broad range of 
practice patterns. However, the steering committee feels that 
the following key findings from these data are important to 
highlight:
• Primary THA and TKA are safe surgical procedures, 
with very low mortality and good outcomes in a high 
percentage of patients. Furthermore, this was consistent 
throughout a number of hospitals across 13 countries. 
• Despite wide practice variations in GLORY, the func-
tional outcomes of the patients appear to have remained 
relatively consistent. This consistency is observed despite 
the geographical and surgical variations intrinsic to the 
GLORY data set.
• The rate of symptomatic VTE is higher than already 
reported in randomized trials. Although nearly all patients 
receive VTE prophylaxis, the actual compliance with 
guidelines6 is suboptimal. Further education regarding 
the nature and content of evidence-based guidelines for 
VTE prophylaxis in THA and TKA patients is therefore 
required. 
• Furthermore, the use of prophylaxis tails off over time, 
even though patients are still at risk of thrombosis.6
• Registries have an important role to play in identifying 
areas that require healthcare management attention, and 
they can therefore have a direct effect on clinical practice. 
Future direCtionS
In GLORY, we have noted a number of clinical practices that 
do not have evidence supporting their effectiveness/safety and 
therefore should be evaluated in controlled clinical trials:
• In 38% of patients (58% of US patients and 14% 
of patients from other countries), a mechanical modal-
ity of prophylaxis was used as well as a pharmacological 
modality. This practice is likely to be performed because 
mechanical prophylaxis when added to pharmacological 
prophylaxis may increase efficacy but is not associated 
with any increased risk of adverse safety outcomes. The 
use of mechanical methods immediately following surgery 
before switching to chemical prophylaxis 1 to 2 days after 
surgery can potentially minimize the bleeding risk while 
providing practical and effective prophylaxis. According 
to the 2004 American College of Chest Physicians (ACCP) 
guidelines, there are no randomized trials comparing mul-
timodal prophylaxis with single modalities, although this 
approach is commonly used in major orthopedic surgery.7 
It is therefore important to fully test this hypothesis in the 
setting of a strictly controlled clinical trial. 
• It was interesting to note that of the 117 US physicians 
participating in GLORY, 101 (86%) gave warfarin for VTE 
prophylaxis to at least 1 patient, and that 52 (51%) of these 
targeted an international normalized ratio (INR) of 1.5 to 1.9. 
This widespread practice is based on physician perceptions for 
Table. GLORY Compliance With Key Suggestions for Good Registry Design 
(made by Alpert JS. Eur Heart J.  2000;21(17):1399-1401)
Design Area Key Suggestion                                                                                       Present in GLORY Design?
Study design  Standardized disease definitions √   
    Standardized sampling techniques √
Data collection Randomized selection of hospitals/clinics or community-wide collection x
    Clear understanding provided to participants on information required √
    Reporting of all collected data √
    Centralization of all data and analysis √
    Professional statistician monitoring all data collection and analysis √
    Accuracy and completeness of individual data sheets should be 
       examined by central center √
    IRB review and approval of registry protocol at each participating site √
    Report the names of all participating investigators √
    Sponsorship of the registry should be disclosed on all reports √
    A PI or steering committee should maintain overall control of all facets 
       of the registry’s running √
Abbreviations:  IRB, institutional review board; PI, principal investigator.
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reduced bleeding risk at no cost to efficacy, but as yet there 
is no conclusive evidence for or against this approach. Data 
from Caprini and colleagues8 suggest that there is improved 
resolution of deep vein thrombosis in patients with a higher 
INR (2.0-3.0), although this was not investigated in the 
GLORY registry.  Given the current lack of clarity about the 
role of low-target INR prophylaxis in orthopedic surgery, it is 
important that a randomized trial comparing this low-target 
INR with the recommended and evidence-based INR of 2.0 to 
3.0 be conducted in order to evaluate the safety and efficacy 
of such an approach. It would also be of interest to look at  the 
results found for PE prevention practices if comparing with 
the American Academy of Orthopaedic Surgeons (AAOS) 
pulmonary embolism prevention guidelines rather than with 
the ACCP guidelines.9
Furthermore, we have also noted a number of apparent 
associations that would need to be further tested. Because 
of the observational nature of GLORY and the potential 
confounding issues found when data are assessed retrospec-
tively, firm conclusions should not be made until these asso-
ciations can be examined in controlled clinical studies:
• The use of blood salvage techniques for blood management 
was seen in 18% of THA and 32% of TKA patients in GLORY. 
Of these patients, 30% of THA and 14% of TKA patients 
had the blood washed in the infusion device. It was therefore 
notable that there appeared to be an increased risk of VTE both 
in-hospital and post-discharge in patients who received blood 
salvage compared with those who did not. This potential asso-
ciation between the blood salvage technique, which may induce 
activation of blood coagulation, and the incidence of VTE needs 
to be fully investigated in a prospective manner. 
• Lower preoperative and postoperative Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC) 
and Short Form-8 Survey (SF-8) scores were found in 
patients who developed a VTE when compared with the 
scores of patients who did not. This finding was consistent 
for both in-hospital and post-discharge VTE events. The 
possibility that poor preoperative function predisposes to 
VTE, and that VTE may lead to worse functional outcome, 
should be examined further. 
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